Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
Stopped early · Phase 3
Conditions studied: Metastatic Melanoma
In brief
The objective is to assess the efficacy and safety of masitinib at 7.5 mg/kg/day in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-Kit and who have not previously been treated for melanoma.
Key facts
- Study ID
- NCT01280565
- Run by
- AB Science
- People needed
- 134
- Starts
- 2011-01-01
- Expected to finish
- 2019-08-01
- Last updated by the study team
- 2020-11-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Blumenthal Cancer Centre — Charlotte, North Carolina, United States
- University Hospital Hradec Králové — Hradec Králové, Czechia
- Hôpital Saint Andre — Bordeaux, France
- Centre Hospitalier LE MANS — Le Mans, France
- Hôpital Sainte Marguerite — Marseille, France
- Klinik und Poliklinik für Hautkrankheiten — Münster, Germany
- Istituto Europeo di Oncologia — Milan, Italy
- N.N.Blokhin Russian Cancer Research Centre — Moscow, Russia
- Hospital General de Valencia — Valencia, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.